NEVADA
|
000-54014
|
20-5093315
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification Number)
|
343 Allerton Ave.
South San Francisco, California 94090
|
(Address of principal executive offices)
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
Common
Stock, par value $0.001 per share
|
VTGN
|
Nasdaq
Capital Market
|
Exhibit No.
|
|
Description
|
|
|
|
|
Press
Release issued by VistaGen Therapeutics, Inc., dated January 6,
2021.
|
|
VistaGen
Therapeutics, Inc.
|
|
|
|
|
Date:
January 6, 2021
|
By:
|
/s/ Shawn K. Singh
|
|
|
Shawn
K. Singh
Chief
Executive Officer
|
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end